Wu Hua-Hsi, Wang Peng-Hui, Yeh Jiun-Yih, Chen Yi-Jen, Yen Ming-Shyen, Huang Rui-Lan, Tsai Yueh-Ju, Yuan Chiou-Chung
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; Immunology Center, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
Taiwan J Obstet Gynecol. 2014 Mar;53(1):30-4. doi: 10.1016/j.tjog.2013.02.002.
Cytokeratin 19 is significant for indicating cancer cells, and Cyfra 21-1 is a fragment of cytokeratin 19. This retrospective study was designed to define the prognostic value of serum Cyfra 21-1 in epithelial ovarian cancers (EOC).
Serum Cyfra 21-1 concentration was obtained from 42 patients with EOC prior to treatment. Various prognostic aspects were examined using univariable and multivariable analyses. The standard serum marker cancer antigen 125 was measured simultaneously and compared in this analysis.
Serum levels of both Cyfra 21-1 and cancer antigen 125 were associated with positive retroperitoneal lymph nodes and platinum resistance; higher levels of Cyfra 21-1 (3.0 ng/mL as the cut-off) were associated with shorter disease-free survival (16 months vs. 28 months, p = 0.001) and overall survival (29 months vs. 41 months, p = 0.007) than lower levels. Further univariable analysis showed that Cyfra 21-1, poor differentiation, and retroperitoneal lymph node metastasis were related to platinum resistance and mortality. Multivariable analysis indicated retroperitoneal lymph node metastasis and serum Cyfra 21-1 were independent risk factors for both disease-free survival and overall survival.
The pretreatment level of serum Cyfra 21-1 had remarkable prognostic significance for EOC, indicating poor survival when it was elevated above 3.0 ng/mL.
细胞角蛋白19对癌细胞的指示具有重要意义，而细胞角蛋白19片段（Cyfra 21-1）是细胞角蛋白19的一个片段。本回顾性研究旨在确定血清Cyfra 21-1在上皮性卵巢癌（EOC）中的预后价值。
收集42例EOC患者治疗前的血清Cyfra 21-1浓度。采用单变量和多变量分析检查各种预后因素。同时检测标准血清标志物癌抗原125并在本分析中进行比较。
血清Cyfra 21-1和癌抗原125水平均与腹膜后淋巴结阳性和铂耐药相关；Cyfra 21-1水平较高（以3.0 ng/mL为临界值）与较低水平相比，无病生存期较短（16个月对28个月，p = 0.001）和总生存期较短（29个月对41个月，p = 0.007）。进一步的单变量分析表明，Cyfra 21-1、低分化和腹膜后淋巴结转移与铂耐药和死亡率相关。多变量分析表明，腹膜后淋巴结转移和血清Cyfra 21-1是无病生存期和总生存期的独立危险因素。
血清Cyfra 21-1的预处理水平对EOC具有显著的预后意义，当其高于3.0 ng/mL时提示生存较差。
